Navigation Links
Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
Date:5/4/2011

NEW YORK, May 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer

http://www.reportlinker.com/p0284821/Triple-Analysis-Leukemia-Lymphoma-and-Pancreatic-Cancer.html

This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia

The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma

The lymphoma report part includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, T-cell lymphoma and Lymphoma (general)). This report part extensively analyses 124 identified targets of lymphoma drugs, organized into 109 drug target strategies, and assesses them in lymphoma.

This part is based on the following publication:

Lymphoma Drug Development Strategies at Work - Define Your Competition

Part III: Pancreatic Cancer

The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.

This part is based on the following publication:

Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia

5.1 The Scope of this Report 29

6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443

7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727

8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728

9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129

11 Disclaimer 1130

12 Drug Index 1131

13 Company Index 1140

Figures: Includes 6 Figures

Tables: Includes 253 Tables

Total Number of Pages: 1,147

Part II: Lymphoma

5.1 The Scope of this Report 22

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (124 Drug Targets) 26-250

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline? (109 Drug Target Strategies and 176 Drugs) 251-280

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline by Type of Compound (6 Different Compound Strategies) 281-312

9 Selecting a Sub-Indication of Lymphoma for Drug Development 313-450

10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator (106 Investigators) 351-524

12 Drug Index 526

13 Company Index 531

Figures: Includes 17 Figures

Tables: Includes 164 Tables

Total Number of Pages: 535

Part III: Pancreatic Cancer

5.1 The Scope of this Report 24

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (171 Drug Targets) 28

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Pancreatic Cancer Therapeutic Pipeline? (142 Drug Target Strategies and 213 Drugs) 333

8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 374

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Pancreatic Cancer Therapeutic Pipeline by Investigator (137 Investigators) 408-599

11 Drug Index 601

12 Company Index 606

Figures: Includes 5 Figures

Tables: Includes 193 Tables

Total Number of Pages: 610

To order this report:

: Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011
2. Reportlinker Adds Latin American Markets for Dental Implants, Final Abutments and Computer Guided Surgery 2011 (Argentina, Brazil and Mexico)
3. Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries)
4. Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis
5. Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis
6. Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition
7. Reportlinker Adds Triple Analysis: Leukemia, Pancreatic Cancer and Prostate Cancer
8. Reportlinker Adds Cancer Reports Bundle
9. Reportlinker Adds Medical Imaging Technologies for Oncology Diagnostics: The Global Market
10. Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
11. Reportlinker Adds Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... The new ... medium and small physician practices, to better grasp and implement HIPAA’s privacy, security, ... guides practices on a well-defined, expert-created path to compliance. HIPAA Institute has positioned ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK ... sSOIP telemedicine stethoscope software that enables the stethoscope stream to go over the ... works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two software elements ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... ... 3, Issue 1 of Patient Experience Journal (PXJ), an international, open access, ... experience. With almost half the issue representing international (non-US) based authors, the third ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... The ... a time to honor the civilian nurses that care for its uniformed service members, ... signed a proclamation in 1974 designating May 6th through May 12th National Nurses Week. ...
(Date:5/2/2016)... ... May 02, 2016 , ... In honor of National Physical Fitness and ... people who share their fitness journey on social media. , The foot care ... award a $100 product voucher each week during May to one winner. , “Whether ...
Breaking Medicine News(10 mins):